Medtronic (MDT) Tops Q2 EPS by 3c, Maintains FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Medtronic, Inc. (MDT) PT Lowered to $142 at Guggenheim
November 24, 2021 8:05 AM ESTGuggenheim analyst Chris Pasquale lowered the price target on Medtronic, Inc. (NYSE: MDT) to $142.00 (from $148.00) while maintaining a Buy rating.
The analyst commented, "MDT reported FY2Q22 revenue below Consensus estimates, though relatively in-line with weakened sentiment, in our view, while adj.... More
Medtronic, Inc. (MDT) PT Lowered to $140 at Stifel
November 23, 2021 5:49 PM ESTStifel analyst Rick Wise lowered the price target on Medtronic, Inc. (NYSE: MDT) to $140.00 (from $145.00) while maintaining a Buy rating following earnings.
The analyst commented, "We were hopeful that Medtronics F2Q22 (Oct.) would reflect more-visible US procedure volume recovery/improvements. This... More
Medtronic, Inc. (MDT) PT Lowered to $145 at Needham & Company
November 23, 2021 1:27 PM ESTNeedham & Company analyst Michael Matson lowered the price target on Medtronic, Inc. (NYSE: MDT) to $145.00 (from $152.00) while maintaining a Buy rating.
The analyst commented, "MDT's F2Q22 revenue missed consensus while EPS beat consensus and organic revenue growth slowed to 2.2% from 19.0% in... More
